The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3476-3485

  Garofalo, Angela ^a   Naumova, Elitza ^a   Manenti, Luigi ^a   Ghilardi, Carmen ^a   Ghisleni, Gabriele ^c   Caniatti, Mario ^c   Colombo, Tina ^b   Cherrington, Julie M ^d   Scanziani, Eugenio ^c   Nicoletti, Maria Ines ^a   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; AUTOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DIAPHRAGM; DOSE RESPONSE; FEMALE; INHIBITION KINETICS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; OMENTUM; OVARY CARCINOMA; PANCREAS; PERITONEAL CAVITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, FIBROBLAST GROWTH FACTOR; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 10744223595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med., 329: 1550-1559, 1993.
2. Runowicz, C. D., Wiernik, P. H., Einzig, A. I., Goldberg, G. L., and Horwitz, S. B. Taxol in ovarian cancer. Cancer (Phila.), 71: 1591-1596, 1993.
3. Rowinsky, E. K., and Donehower, R. C. Paclitaxel. N. Engl. J. Med., 332: 1004-1014, 1995.
4. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1996.
5. Zhang, H. T., and Harris, A. L. Anti-angiogenic therapies in cancer clinical trials. Exp. Opin. Investig. Drugs, 7: 1629-1655, 1998.
6. Teicher, B. A. A system approach to cancer therapy. Cancer Metastasis Rev., 15: 247-272, 1996.
7. Giavazzi, R., Garofalo, A., Ferri, C., Lucchini, V., Bone, E. A., Chiari, S., Brown, P. D., Nicoletti, M. I., and Taraboletti, G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the anti-tumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res., 4: 985-992, 1998.
8. Hollingsworth, H. C., Kohn, E. C., Steinberg, S. M., Rothenberg, M. L., and Merino, M. J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol., 147: 33-41, 1995.
9. Alvarez, A. A., Krigman, H. R., Whitaker, R. S., Dodge, R. K., and Rodriguez, G. C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res., 5: 587-591, 1999.
10. Olson, T. A., Mohanraj, D., Carson, L. F., and Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res., 54: 276-280, 1994.
11. Barton, D. P., Cai, A., Wendt, K., Young, M., Gamero, A., and De Cesare, S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin. Cancer Res., 3: 1579-1586, 1997.
12. Fox, S. B., Gasparini, G., and Harris, A. L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol., 2: 278-289, 2001.
13. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 77: 527-543, 1999.
14. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
15. Ke-Lin, Qu-Hong, Nagy, J. A., Eckelhoefer, I. A., Masse, E. M., Dvorak, A. M., and Dvorak, H. F. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur. J. Cancer, 32A: 2467-2473, 1996.
16. Luo, J. C., Yamaguchi, S., Shinkai, A., Shitara, K., and Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors, Cancer Res., 58: 2652-2660, 1998.
17. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. (Bethesda), 90: 447-454, 1998.
18. Mesiano, S., Ferrara, N., and Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer. Am. J. Pathol., 153: 1249-1256, 1998.
19. Veikkola, T., and Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol., 9: 211-220, 1999.
20. Ferrara, N., and Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 5: 1359-1364, 1999.
21. Rifkin, D. B., and Moscatelli, D. Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol., 109: 1-6, 1989.
22. Folkman, J., and Klagsbrun, M. Angiogenic factors. Science (Wash. DC), 235: 442-447, 1987.
23. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell, 66: 1095-1104, 1991.
24. Asahara, T., Bauters, C., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., and Isner, J. M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation, 92: 365-371, 1995.
25. Mignatti, P., Morimoto, T., and Rifkin, D. B. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc. Natl. Acad. Sci. USA, 88: 11007-1101, 1991.
26. Gross, J. L., Herblin, W. F., Dusak, B. A., Czerniak, P., Diamond, M. D., Sun, T., Eidsvoog, K., Dexter, D. L., and Yayon, A. Effects of modulation of basic fibroblast growth factor on tumor in vivo. J. Natl. Cancer Inst. (Bethesda), 85: 121-131, 1993.
27. Hermansson, M., Nister, M., Betsholtz, C., Heldin, C. H., Westermark, B., and Funa, K. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc. Natl. Acad. Sci. USA, 85: 7748-7752. 1988.
28. Plate, K. H., Breier, G., Farrell, C. L., and Risau, W. Platelet-derived growth factor receptor β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Investig., 67: 529-534, 1992.
29. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Wash. DC), 277: 242-245, 1997.
30. Sariban, E., Sitaras, N. M., Antoniades, H. N., Kufe, D. W., and Pantazis, P. Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines. J. Clin. Investig., 82: 1157-1164, 1988.
31. Henriksen, R., Funa, K., Wilander, E., Backstrom, T., Ridderheim, M., and Oberg, K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasm. Cancer Res., 53: 4550-4554, 1993.
32. Fujimoto, J., Ichigo, S., Hori, M., Hirose, R., Sakaguchi, H., and Tamaja, T. Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur. J. Gynaecol. Oncol., 18: 349-352, 1997.
33. Cherrington, J. M., Strawn, L. M., and Shawver. L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res., 79: 1-38, 2000.
34. Laird, A. D., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A. T., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington, J. M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 60: 4152-4160, 2000.
35. Shaheen, R. M., Tseng, W. W., Davis, D. V., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., Bucana, C. D., McMahon, G., and Ellis, L. M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res., 61: 1464-1468, 2001.
36. Masazza, G., Tomasoni, A., Lucchini, V., Allavena, P., Erba, E., Colombo, N., Mantovani, A., D'Incalci, M., Mangioni, C., and Giavazzi, R. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer, 44: 494-500, 1989.
37. Codegoni, A. M., Nicoletti, M. I., Buraggi, G., Valoti, G., Giavazzi, R., D'Incalci, M., Landoni, F., Maneo, A., and Broggini, M. Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur. J. Cancer, 9: 1432-1438, 1998.
38. Belotti, D., Rieppi, M., Nicoletti, M. I., Casazza, A. M., Fojo, T., Taraboletti, G., and Giavazzi, R. Paclitaxel (Taxol) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res., 2: 1725-1730, 1996.
39. Giavazzi, R., Nicoletti, M. I., Chirivi, R. G. S., Hemingway, I., Bernasconi, S., Allavena, P., and Gearing, A. J. H. Soluble intercellular adhesion molecule-1 (ICAM-1) is released into the serum and ascites of human ovarian carcinoma patients and in nude mice bearing tumour xenografts. Eur. J. Cancer, 30: 1865-1870, 1994.
40. Gibbs, J. B. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Investig., 105: 9-13, 2000.
41. Strawn, L. M., and Shawver, L. K. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Investig. Drugs, 7: 553-573, 1998.
42. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Wenger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K., Schneider, M. R., Drevs, J., Martiny-Baron, G., Totzke, F., and Marmé, D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 60: 2178-2189, 2000.
43. Mendel, D. B., Laird, A. D., Smolich, B. D., Blake, R. A., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., and Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des., 15: 29-41, 2000.
44. Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J. J., and Fidler, I. J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol., 16: 445-454, 2000.
45. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
46. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
47. Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., and Ellis, L. M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J., 15: 1239-1241, 2001.
48. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel, D. B., and Cherrington, J. M. SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002.
49. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., Sioussat, T. M., and Dvorak, H. F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res., 55: 360-368, 1995.
50. Luo, J. C., Toyoda, M., and Shibuya, M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res., 58: 2594-2600, 1998.
51. Arteaga, C. L. Is one promiscuous drug against multiple targets better than combinations of molecule-specific drug? Clin. Cancer Res., 9: 1231-1232, 2003.
52. Herbst, R. S., Takeuchi, H., and Teicher, B. A. Paclitaxel/carboplatin administration along with antiangiogenic, therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol., 41: 497-504, 1998.
53. Pietras, K., Rubin, K., Sjoblom, T., Buchdunger, E., Sjoquist, M., Heldin, C., and Ostman, A. Inhibition of PDGF receptor signaling in stroma enanches antitumor effect of chemotherapy. Cancer Res., 62: 5476-5484, 2002.
54. Miller, K. D., Sweeney, C. J., and Sledge, G. W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol., 19: 1195-1206, 2001.
55. Schirner, M., Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev., 19: 67-73, 2000.
56. Hanahan, D., Bergers, G., and Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig., 105: 1045-1047, 2000.
57. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained regression without over toxicity. J. Clin. Investig., 105: 15-24, 2000.
58. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.